awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q53167144-DFB7E4B9-6E7E-41D5-A8F6-4EE290F09C91
Q53167144-DFB7E4B9-6E7E-41D5-A8F6-4EE290F09C91
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53167144-DFB7E4B9-6E7E-41D5-A8F6-4EE290F09C91
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).
P2860
Q53167144-DFB7E4B9-6E7E-41D5-A8F6-4EE290F09C91
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53167144-DFB7E4B9-6E7E-41D5-A8F6-4EE290F09C91
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1bc6f233ae68aa7e52200598be2194583e8eac72
P2860
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.